Pharmacogenetics of adverse effects due to antiretroviral drugs.

Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Peré Domingo(Hospital de Sant Pau), Victoria Sánchez(Hospital Arnau de Vilanova), Consuelo Viladés(Hospital Universitario Fundación Jiménez Díaz), Miguel López-Dupla, Sergi Veloso, Joaquim Peraire(Instituto de Salud Carlos III), Mar Gutiérrez, Félix Gutiérrez(Universitat de Miguel Hernández d'Elx), Gràcia Mateo(Evidence (Italy)), Montserrat Olona

PubMed

June 14, 2010

Cited by 47

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy

|JAMA|2016|1.4k

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

|The Lancet|2019|1k

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19

|JAMA|2021|728

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

|The Lancet Infectious Diseases|2015|143

Relationship between current level of immunodeficiency and non‐acquired immunodeficiency syndrome‐defining malignancies

|Cancer|2010|141